

Sprint Bioscience Q4 2022 - Temporary setbacks

Redeye comments on Sprint Bioscience's Q4 2022 report, and we judge that the company is closing in on a licensing deal for its VADA project H1 2023e after some setbacks in recent months. We tweak our estimates and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Sprint Bioscience Q4 2022 - Temporary setbacks](#)